Detection and quantification of anti-rabies glycoprotein antibodies: current state and perspectives

Maria Celeste Rodriguez 1 · Diego Fontana 1 · Ernesto Garay 1 · Claudio Prieto 2

Received: 26 March 2021 / Revised: 6 August 2021 / Accepted: 10 August 2021
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021

Abstract
Rabies is an ancient fatal disease with no other available treatment than post-exposure vaccination, where the bite of infected animals, mainly dogs, is the leading cause of its transmission to human beings. In this context, global vaccination campaigns of companion animals, as well as wildlife reservoirs vaccination, are key factors to achieve the “Zero by 30” plan that pursues the eradication of dog-mediated human rabies by 2030. Rabies virus-neutralizing antibodies (VNAs) play an essential role in the disease protection, as it correlates with an adequate immune response and allows evaluating pre- or post-exposure prophylaxis efficacy. Hence, counting with reliable, accurate, and robust serological tests is of paramount importance. Currently, RFFIT and FAVN are the gold standard VNAs tests recommended by both the WHO and the OIE. Despite these methodologies are efficient and widely used, they present several drawbacks, as they are less easily to standardize and require the use of live rabies virus, containment facilities, and skilled professionals. Thus, in this review, we describe the state-of-the-art of alternative analytical methodologies currently available for rabies serology, with novel approaches based on pseudotyped recombinant viruses and emphasizing in the antigen binding methodologies that detect and quantify antibodies against the rabies glycoprotein. We discussed the wide range of assays that are interesting tools for a faster measurement of anti-rabies glycoprotein antibodies and, in some cases, less complex and more versatile than the gold standard methods. Finally, we discussed the key issues during the design and optimization steps of ELISA assays, highlighting the importance of validation and standardization procedures to improve rabies serology tests and, as a consequence, their results.

Key points
- An exhaustive revision of rabies serology testing was made.
- No rabies serology assay can be thought as better than others for all intents and purposes.
- The validation procedure guarantees reliable and consistent results among the globe.

Keywords Rabies · Serology test · Glycoprotein · Neutralizing antibodies

Introduction
Throughout human history, zoonoses have become one of the greatest challenges to public health. Globally, it is estimated that about one billion cases of severe illnesses and millions of deaths occur every year from zoonoses. It is not a coincidence that the COVID-19 pandemic broke out as a result of altering environmental conditions for wildlife and the exploitation of natural resources to satisfy the demands of the population in constant growth. In particular, rabies is one of the most lethal zoonoses in the world, with a mortality approaching 100%. This disease is caused by a virus of the *Rhabdoviridae* family, *Lyssavirus* genus, provoking between 40,000 and 60,000
human deaths per year in over 150 countries, with 95% of cases occurring in Africa and Asia (World Health Organization 2018). The leading mechanism of transmission is by an animal bite, throughout the saliva of the infected host. Firstly, the virus infects peripheral nerves and, then, moves to the central nervous system. However, while rabies is fatal once symptoms appear, it is preventable due to the relatively long incubation period between virus entry and development of clinical disease (Johnson et al. 2010; Ives et al. 2019). Thus, rabies post-exposure prophylaxis (PEP), together with domestic animals and wildlife reservoir vaccination and human pre-exposure prophylaxis (PREP), represents the main strategies to mitigate and control rabies disease (Ives et al. 2019) (Fig. 1).

Rabies immune response involves both cell-mediated and humoral immunity; however, it is recognized that virus-neutralizing antibodies (VNAs) are critical for protection against rabies virus (RABV) infection (Katz et al. 2017). RABV is an enveloped virus, and the glycoprotein (G) is anchored on the viral membrane. The G is the only surface viral protein and the only viral product known to be capable of eliciting the production of VNAs (Flamand et al. 1993; Fallahi 2005; Schnell et al. 2010). The VNAs interact with the virus, blocking their entrance to the cell, preventing (or mitigating) the course of the infection. Therefore, measure of VNAs levels is of paramount importance (Johnson et al. 2010; Moore et al. 2017; Zhao et al. 2019). Rabies serology tests are invaluable tools for determining the acquired immune response after infection and the effectiveness of vaccination campaigns of humans and wildlife (Moore et al. 2013; Moore et al. 2017; Moore and Gordon 2020).

Virus neutralization assays (VNAs) are cell-based or in vivo assays that detect the functional activity of Abs in the serum, plasma, or cerebrospinal fluid against live virus. The first assay developed to quantify rabies VNAs was the mouse neutralization test (MNT) (Webster and Dawson 1935), an in vivo assay where mice are intracerebrally inoculated with active RABV, previously incubated with diluted serum samples. The level of VNAs in the sample is evidenced by the survival of inoculated animals, where a higher percentage of survival is related to a higher VNAs titer. Because of the technical complexity, the difficulty to standardize the assay involving the use of live animals, and the growing tendency to substitute the animal use (3 R principle), it has been replaced in many laboratories around the world with some exceptions in developing countries (World Health Organization 2018).

Fig. 1 Rabies virus infection and the importance of pre-exposure prophylaxis (PREP) and post-exposure prophylaxis (PEP) in rabies control and prevention. Both PREP and PEP are mainly based on vaccination of individuals in order to induce an immune response where antibodies play a central role for the control of the infection. Besides, human rabies immunoglobulins (HRIGs) are frequently administered in PEP protocols.
To date, only two rabies VNAs tests are considered as the gold standard methods for rabies serology and recommended by the World Health Organization (WHO) and the World Organization for Animal Health (OIE): the RFFIT (rapid fluorescent focus inhibition test) (Smith et al. 1973) and the FAVN (fluorescent antibody virus neutralization) test (Cliquet et al. 1998). These methods were designed to mimic the in vivo assay, using BHK-21 cells, which are highly susceptible to RABV infection (Fig. 2). Result interpretation is the main difference between both assays: in the former, the number of infected focus per serum dilution is used to calculate the ED$_{50}$ (50% effective dose) neutralization titer and converted to IU/mL if a reference standard is included in the assay (World Health Organization 2018)(Fig. 2A), whereas the latter is an “all or nothing” approach. Here, BHK-21 cells are cultured on 96-well plates instead of the 8-well chambers used on RFFIT assay; thereafter, each well is marked as positive or negative depending on the presence of infected cells on it, thereby increasing the accuracy and the quality of the test results (World Health Organization 2018) (Fig. 2B). These VNAs tests exhibit several drawbacks, as they are less easily standardized and require the use of live RABV, containment facilities, and skilled professionals, among others. Therefore, there is a need to develop alternative techniques to assess rabies control and surveillance.

Hence, alternative methods with greater assurance of consistent results and less time-consuming, as ELISA assays, are nowadays considered as acceptable to detect anti-rabies...
glycoprotein antibodies (Abs). Indeed, there are several works that demonstrated a good correlation between these assays and VNAs tests, based only on detecting and measuring anti-G protein antibodies (Welch et al. 2009; Wasniewski et al. 2016; Moore et al. 2017). Thus, in this review, we describe the state-of-the-art of the analytical methodologies currently available for rabies serology as an alternative to gold standard tests, taking into account other novel recombinant VNAs test approaches and the wide range of antigen binding assays. These are interesting tools for a faster measurement of anti-rabies glycoprotein antibodies and, in some cases, less complex and more versatile than the gold standard methods. However, before selecting the most suitable method, it is essential to define the fit-for-purpose of the assay.

Alternative for the measurement of VNAs: pseudotyped neutralization assays

In the last decades, recombinant viral vectors pseudotyped with a heterologous glycoprotein have been widely used for the establishment of safe and versatile serology tests. Using these vectors for the detection of VNAs (in vitro or in vivo), multiple strains or genotypes of viruses can be evaluated in a safer way. The recombinant vectors are normally produced by transient transfection methods, and the obtained viral particles are not replicative; thus, lower biohazard practices are needed (Ferrara and Temperton 2018). Lentiviruses are the most common recombinant vectors used for this purpose, being applied for a variety of enveloped viruses such as Ebola, MERS, Hepatitis C, influenza, and, more recently, for SARS-CoV-2. The envelope protein, the core and its genome, containing a reporter, is the backbone of the pseudotyped system. Several reporters are employed in the pseudotyped system being the fluorescent proteins (more often GFP) and luciferase the most commonly used reporter, due to its higher sensitivity and versatility, enabling high-throughput screening. Thereafter, the signal is measured using a fluorescent microscope or a flow cytometer for the former and a luminometer for the latter, where a cell lysis step prior to acquisition is necessary (Temperont et al. 2005; Fontana et al. 2015; Nie et al. 2017; Crawford et al. 2020; Nie et al. 2020; Yang et al. 2020) (Fig. 3). To guarantee comparable results among assays, titers should be reported as median tissue culture infection dose (TCID50). Besides, it is important to establish the producer cell line (more often HEK293T), the transfection method (chemical or physical), culture conditions, and the harvest time, to standardize the LV production protocol assessing consistent LV titers and as a consequence, consistency, accuracy, and reproducibly results.

For rabies, these recombinant viruses are pseudotyped with the G protein as the envelope protein (Fig. 3). Wright et al. described a strong correlation between FAVN and the pseudotyped assay, obtaining a specificity of 100 % and a sensitivity of 94.4% (Wright et al. 2008; Wright et al. 2009). Later, Nie et al. developed a highly efficient rabies pseudotyped lentivirus production platform and a robust in vitro and in vivo neutralization assays for the evaluation of rabies vaccine. They compared these methods with current RFFIT test, showing a good linear correlation between the two assays ($R^2=0.946,<0.001$) but demonstrating better reproducibility for the pseudotyped assay (Nie et al. 2017).

Antigen binding assays

Besides VNAs test, other types of methodologies commonly denominated antigen (Ag) binding assays have been developed for rabies serology. In these assays, the Abs present in serum, plasma, or other body fluids are evaluated by its ability to bind to the rabies G protein, either purified from the whole virus, recombinantly expressed, or using peptides that represent epitopes exhibited in the G protein amino acid sequence. A variety of methods have been developed and validated for its use in serology testing (Table 1).

Nowadays, ELISA assays are considered as the more suitable alternative approach for rabies serology, providing consistent results in several laboratories, particularly for quantitation of Abs titer in PEP and seroprevalence surveys in different wildlife reservoirs. Also, ELISA could be used to quantify human anti-rabies Abs titers following vaccination (Cliquet et al. 2004; Wasniewski et al. 2016). There are several types of ELISA used in serological methods, which vary in the antigen-antibody detection format. Besides, there are several detection systems, as biotin-avidin system conjugated to HRP, a secondary antibody conjugated to HRP, or a bacterial protein A/G conjugated to HRP that recognize the Fc portion of the Igs. That is why elucidating each step of the ELISA format can help us in interpreting the results correctly.

In the indirect ELISA (iELISA) format, the Ag is fixed to the solid phase in the first step of the assay, and, later, the incubation of samples (that contains the Rabies Igs) allows the Ag-Ab interaction. The detection systems usually involve a secondary antibody conjugated to the HRP enzyme. This secondary antibody can be species specific which may limit the assay versatility (Cliquet et al. 2000; Cliquet et al. 2003; Zhao et al. 2019), Igs specific (more often anti-IgM or anti-IgG) (Zajac 2019), or recognizing the Fc portion of the Abs, as the protein A/G system conjugated to HRP is employed (De Toledo Piza et al. 1999; Cliquet et al. 2004; Feyssaguet et al. 2007). The main advantage of the latter detection system is that the method can be applied to samples of different species. However, the protein A/G does not bind with the same affinity to all Igs subtypes, and it also varies between species; indeed, it is known that protein A binds preferentially to IgM or IgG, but not to IgG3 subclass.
Hence, there could be some variations in the Abs quantitation (or detection) depending on the sample (type, timing, species); thus, special care in this kind of assay must be taken, mainly during the assay result interpretation. On the other hand, if the aim of the study is to determine the proportion of IgG/IgM in the course of rabies infection or after rabies vaccination, the detection system employing anti-IgM and anti-IgG is highly desirable. However, if the goal is to develop a good estimator of VNAs, the latter system is not the best, as it has been established that only IgGs can neutralize and protect against RABV infection. The function of IgM may be limited due to its pentameric structure, preventing the tissue penetration of IgM (Katz et al. 2017).

Two commercial iELISA assays are based on HRP-conjugated protein A, the SERELISA® (Rabies Ab Mono Indirect) and PLATELIA® II Rabies kit (Bio-Rad). There are several reports that compared their results with the ones of VNAs assays. The SERELISA® test was described by the OIE as a screening tool to control rabies Abs in vaccinated dogs and cats, but due to the lack of sensitivity, all negative results must be confirmed in a VNAs test (Cliquet et al. 2004). Further collaborative studies demonstrated a high rate of false positive results in several laboratories (Servat and Cliquet 2006; Wasniewski et al. 2016). Regarding the PLATELIA® Rabies II kit (certified by the OIE), Feyssaguet et al described this test as a qualitative and semi-quantitative format, which exhibited a good correlation with RFFIT test for vaccinated and unvaccinated human serum sample (Feyssaguet et al. 2007). Besides, Welch et al. (2009) described good correlation between PLATELIA® and RFFIT assay in human sera samples and better than those obtained when compared to an alternative indirect ELISA kit, DGR Rabies Virus IgG Ab ELISA (DRG International), with the RFFIT (Welch et al. 2009). Moreover, the evaluation of the PLATELIA® II (ad usum veterinarium) for PEP of domestic and wildlife carnivores revealed different results between studies. Servat et al. established a threshold value of 0.5 EU/mL (harmonized with the 0.5 IU/mL) and validated these assays, obtaining good correlation with the FAVN test (Servat et al. 2007). By the contrary, a large-scale study on pet domestic carnivores’ samples significantly differed with the previously mentioned study, establishing a new cut-off value of 0.3 EU/mL to maintain the assay sensitivity but with a reduction in its specificity. These variations between studies could be due to certain
| Assay                        | Type                          | Coated antigen                          | Detection system                              | Species              | Species analytical method parameters                                                                 | References                          |
|-----------------------------|-------------------------------|-----------------------------------------|-----------------------------------------------|----------------------|--------------------------------------------------------------------------------------------------------|-------------------------------------|
| **SERELISA® Rabies Ab Mono**| Qualitative indirect ELISA    | Inactivated G52 (Pasteur derivative) rabies virus strain | Horseradish peroxidase-Protein A               | Domestic carnivores | Lack of sensitivity 50% of participants, rate of false positive result 25% of laboratories (N=16 laboratories. Reference method: FAVN/RFFIT) | Cliquet et al. (2004); Servat and Cliquet (2006) |
| **PLATELIA® Rabies II kit** | Qualitative or semi-quantitative Indirect ELISA | Purified glycoprotein from virus (PV strain) | Horseradish peroxidase-Protein A               | Human                | 98.6% sensitivity; 99.4% specificity (threshold: 0.5 IU/mL; reference method: RFFIT) LOD: 0.05 EU/mL (0.5 IU/mL corresponds with 0.5 EU/mL) | Feyssaguet et al. (2007) |
| **PLATELIA® Rabies II kit (ad usum veterinarium)** | Qualitative or semi-quantitative Indirect ELISA | Purified glycoprotein from virus (PV strain) | Horseradish peroxidase-Protein A (from Staphylococcus aureus) | Domestic carnivores and wildlife | 78.2% sensitivity; 100% specificity (threshold: 0.5 EU/mL. Collaborative study. Reference method: FAVN) | Servat et al. (2007); Wasniewski et al. (2014) |
| cELISA                      | Quantitative cELISA           | Mab-D1 labelled with horseradish peroxidase (HRPO) | Mab-D1 anti-human IgG and horseradish peroxidase-Protein A (HRPO) | Equine, human         | Linearity: 430 and 861 IU/mL for the F(ab)2-ERIGs batches and between 175 and 350 IU/mL for the HRIGs batches | Korimbocus et al. (2016) |
| BioPro® Rabies ELISA Ab kit | Qualitative bELISA            | Crude racoon glycoprotein                | Streptavidin-biotin                            | Fox and racoon dogs  | 100% sensitivity (N=20 laboratories)/95.8–97.9% sensitivity (N=5 laboratories)/100% specificity (N=21 laboratories)/66.7–93.3% specificity (N=4 laboratories) (threshold: 40% of positivity. Collaborative study. Reference method: FAVN) | Wasniewski et al. (2016) |
| bELISA                      | Quantitative bELISA           | Purified RV-VLPs                         | HRP-conjugated streptavidin                    | Multispecies          | Linearity: 0.148–1.0 IU/mL LOD: 0.06 EU/mL (Human Rabies IgG Ph. Eur. Reference Standard). Accuracy was demonstrated (MNT, Plateelia®) | Fontana et al. (2020) |
| ECL                         | Qualitative ELISA-based technique | Carbon electrode plated with purified Glycoprotein G | Sulfo-Tag-Streptavidin                         | Human, dog, racoon    | Sensitivity 100%. Specificity 95% for human samples. Sensitivity 96%. Specificity 95% for field animal sample (threshold: 0.15 IU/mL. Reference method: RFFIT) | Ma et al. (2012) |
| RAPINA                      | Qualitative immunochromatography | Anti-G mAb conjugated with colloidal gold | Red band formation: inadequate level of VNA    | Human                | Sensitivity 100%. Specificity 98.34 (Reference method: RFFIT) | Thi Nguyen et al. (2015) |
modifications during the manufacturing process of the kit (Wasniewski et al. 2014).

Competitive ELISA (cELISA) consists in fixing the Ag to the solid phase, and the Abs present in the sample compete with an enzyme-labeled Ab for binding to the Ag. Thus, in this assay, the higher the signal, the lesser the concentration of Ab in the test sample (Zhang et al. 2009). Another alternative of this format is the one described by Korimbocus et al. for potency testing of equine anti-rabies sera, employing the Mab D1 clone that recognize one of the immunodominant epitopes of the rabies glycoprotein involves in the induction of VNAs (site III) (Jallet et al. 1999), demonstrating a good correlation with MNT assay (Korimbocus et al. 2016). They also evaluated human anti-rabies Igs, obtaining higher and more heterogeneous titers in comparison with PLATELIA® Rabies II and RFFIT.

Blocking ELISA (bELISA) is another format of ELISA assay, where the Ag is also fixed to the plate, but the Abs present in the test sample block the next step, that is, the addition of an enzyme-labeled Ab that binds to the Ag (Fig. 4). Hence, and similar to cELISA, the higher the signal, the lesser the Ab amount in the test sample. An example of a commercial bELISA is the BioPro Rabies ELISA Ab kit (O. K. SERVIS BioPro) that employed crude glycoprotein as coated-antigen and streptavidin-biotin as detection system. Wasniewski and Cliquet compared the BioPro performance with the one of the PLATELIA® Rabies II kits (ad usum veterinarium), determining that the former exhibited better sensitivity and a good correlation with the FAVN test in serum samples of domestic carnivores (Wasniewski and Cliquet 2011). Further studies demonstrated good correlation with FAVN in serum sample of orally vaccinated fox and raccoon dogs (Wasniewski et al. 2013). Besides, BioPro ELISA was further validated throughout an international study involving serum samples from foxes and raccoon dogs vaccinated with different vaccine strains available in Europe (Wasniewski et al. 2016). Dascalu et al. also demonstrated good correlations with the FAVN test for orally vaccinated wild boars and foxes (Dascalu et al. 2019).

Recently, our group has published a validated bELISA for multispecies serum rabies immunoglobulins quantitation employing purified rabies virus-like particles (RV-VLPs) as

---

**Fig. 4** A schematic representation of bELISA assay. First, the antigen is immobilized in 96-well plates (1). Second, Abs present in the serum sample recognizes an epitope of the target antigen (2). Third, a biotin-conjugated Ab interacts with the Ag not blocked by the Abs of the test sample (3). Fourth, a streptavidin-peroxidase conjugate interacts with the biotin of the conjugated Ab (4). The peroxidase reacts with a substrate to produce a detectable signal (5). Here, the higher the signal, the lesser the Ab amount in the test serum samples.
the coated antigen and a biotin-conjugated monoclonal Abs as detection system (Fig. 4). We demonstrated a good correlation of the bELISA with the PLATELIA® Rabies II kit and the MNT test (Fontana et al. 2020). Despite further characterization must be performed, evaluating a bigger serum sample panel, and that the assay reproducibility must be guaranteed, we postulated this assay as a potential alternative to the gold standard methods in PEP schemes and within rabies surveillance programs.

Other methods have also been developed and appeared to be promising alternatives, exhibiting good correlation with the RFFIT. For instance, an electrochemiluminescence (ECL) adaptation of a bELISA using ECL labels and carbon electrode plates to detect binding events presented higher sensitivity and faster results compared to traditional ELISA detection methods (Ma et al. 2012). Furthermore, indirect fluorescent antibody test is also a semi-quantitative test for rabies immunoglobulins detection where the presence of rabies Igs is assessed by a fluorescence signal, requiring as little as 1.5 h to obtain the result. However, a fluorescence microscope is needed (Messenger and Rupprecht 2015). In addition, RAPINA (rapid neutralizing antibody) test based on immunochromatography principle was proposed as a fast alternative method to detect the presence of neutralizing Abs in human serum samples (Shiota et al. 2009). The latter could be an interesting alternative technique for initial screening methods for fieldwork (Thi Nguyen et al. 2015).

**Design, optimization, and validation of Ag binding assays**

As we mentioned, the most effective strategy to control rabies and mitigate its effects are vaccinations campaigns. Hence, it is of paramount importance counting with serology assays allowing accurate and consistent results. In this context, despite ELISAs sometimes fail in the accurate estimation of the potential acquired immunity after infection or vaccination, as functional and non-functional Abs are measured, several others have proven a good correlation with the gold standard assays. Besides, we must not deny all the inherent characteristics of this technique that are a benefit in comparison with gold standard assays: safer, not requiring (in general) virus manipulation, versatility, high-throughput, high consistent results, less time, and associated cost. Finally, another point to consider is that ELISAs are flexible techniques, easily adaptable to laboratories of low-level complexity, making it a particularly interesting candidate in developing countries where rabies is endemic. Therefore, we will briefly discuss the main topics to consider during the development, optimization, and validation of ELISA assays.

When designing an assay, it should be borne in mind the “why” and the “what for” of this assay, that is, the aim and the scope of the analytical test that will guide the selection of the best ELISA platform. Briefly, the ELISA format will be conditioned by the quality and the type of input materials: (i) purity, type of antigen; (ii) type of capture (if needed) and detection antibody (polyclonal or monoclonal Abs, antigenic sites, isotypes); and (ii) detection system, that also, will influence in the sensitivity and the LOD and LOQ of the technique. Generally, fluorescence techniques exhibit a higher sensitivity than colorimetric assay, requiring less amount of the test sample. Besides, the properties of the test sample (type, source, quality, accessibility) will condition the sample treatments: for instance, the proper dilution to guarantee its detection but avoid the matrix effect or the need (or not) to implement a serum heat-inactivation protocol, avoiding proportional systematic errors.

Next, once an ELISA format has been chosen, identifying the critical step/s of the assay should be crucial and can be determined through a screening step, where many factors are studied to identify those having a significant effect on the analyzed response, throughout a design of experiment (DoE). Here, specialized knowledge and experience, together with data from literature, will facilitate the task. The coated-antigen characteristics are probably one of the most crucial steps in the ELISA assay together with the amount and type of capture/detection Abs. For instance, the use of rabies G protein as the coating Ag is more relevant when assessing the oral vaccination efficacy than the whole virus, as VNAs are primarily directed against the glycoprotein. Thus, it will be better to use the glycoprotein as the coated Ag. Besides, the degree of purity of the coated-Ag may influence the assay selectivity. It has been shown that purified Ag provides higher homogeneity, lesser interfering substances, and a better evaluation of VNAs (Zhao et al. 2019). However, it has also been reported that the Ag purification protocols may affect the immunogenicity of the rabies G protein (Wasniewski and Cliquet 2011; Wasniewski et al. 2013).

Once the critical factors have been identified, the optimization step must be followed, using a multivariate approach, as an “optimization” procedure performed by OVAT (one variable at a time) does not guarantee at all that the real optimum will be hit (Leardi 2009). By the contrary, in a multivariate strategy, significant factors (at different levels) are studied simultaneously in a predefined number of experiments (Goicochea 2018). In our previous work (Fontana et al. 2020), an optimization multivariate strategy was followed which allowed us to identify the purified RV-VLPs and the rabies glycoprotein monoclonal antibody (mAb AB5) as the key components of this assay. In the RV-VLPs, the rabies G is presented in high density in the surface of the particles in its trimeric form (Fontana et al. 2015). Besides, the selected detection system (streptavidin-peroxidase) influences the assay sensitivity, so it was selected as an additional variable to be optimized. Moreover, we demonstrated that the mAb AB5 recognized rabies G on its native state-structure, making it
an invaluable feature for this assay, as it can recognize essential epitopes for virus neutralization.

After the optimization process of the assay, it is essential to validate and standardize the method to obtain consistent and comparable results. The goal of an assay validation is to provide assurance that the method is likely to produce results that are fit-for-purpose. Hence, we must differentiate between the aim of a qualitative and a quantitative ELISA assay. The aim of the former is to assess if the analyte (in this case, rabies IgG) is present or not in the test sample and which is the minimum level of detection (cut-off). By the contrary, in the latter assay, a limit of quantitation (LOQ) must be established, and the amount of the analyte in the test sample is determined by comparing with the reference standard’s response. The validation procedure of the test will be not the same if it is a qualitative or a quantitative assay. Indeed, the extent of the validation procedure depends on the status of the assay, and it is determined by the customer needs or as laid down on regulations. For qualitative methods, it is essential to determine the sensitivity (or its inverse false negative rate) and specificity (or its inverse false positive rate) through a ROC curve, finding the optimal cut-off value with a broad spectrum of test samples and avoiding bias (Hajian-Tilaki 2013). In these types of assays, establishing the cut-off value is critical. That is, in part, because the higher the threshold value, the lesser the false positive rate and, thus, a truly guarantee of seroconversion, whereas for quantitative assay, the sensitivity, analytical sensitivity, linearity, limit of detection, LOQ, selectivity, robustness, accuracy, and precision (at least repeatability and intermediate precision) must be evaluated. In addition, the stability is also important. The use of a serum reference standard with known stability is also essential. If a collaboration study is performed, the assay’s reproducibility can be determined to standardize the procedure.

As we previously mentioned, sample characteristics (e.g., matrix, stability, timing, quality, cross-reactivity Abs) are other essential aspects to consider during the validation procedure. The sample matrix can contribute or interfere with the analyte signal, compromising the assay’s selectivity and accuracy. Thus, beside the employment of the corresponding blanks (reactive and sample), the matrix of the sample must be characterized and studied through a different statistical test as recovery or elliptical joint confidence region (EJCR) test (Olivieri 2015), by comparing the signal of the reference and the reference embedded in a certain matrix.

Finally, it is essential to demonstrate the correlation between the developed ELISA assay and the gold standard methods. Hence, we would like to add a final commentary: several works state a good correlation between both assays employing only the $R^2$ coefficient. However, Pearson’s coefficient only measures the variation of one variable with respect to the other but not its degree of agreement. Hence, it does not per se provide any information and should be complemented with Bland and Atman diagram test for quantitative methods and Cohen’s Kappa or McNemar’s test for qualitative methods or another alternative method as EJCR test.

**Conclusions and future perspectives**

Rabies is one of the most lethal worldwide infection diseases. Tens of thousands of deaths are reported annually, but the official figures are believed to be highly underestimated (Banyard et al. 2013). In this scenario, PEP and PREP constitute the main tools in rabies control. In this context, serology is a critical component for rabies surveillance and prevention programs to mitigate its risk in human beings and in domestic and wildlife animals. Currently, RFFIT and FAVN are still being the gold standard VNAs assays for rabies serology test. However, different assays employing pseudotyped recombinant viruses represent a promising and safer alternative to the conventional methods, characterized by a good reproducibility and sensitivity performance. On the other hand, ELISA and other Ag binding assays are considered acceptable for anti-rabies Abs detection, exhibiting greater assurance of consistent results and less time consuming than VNAs tests. However, no method is better than another, and the selection will depend on its fit-for-purpose, meaning that the applied serology test can solve a specific problem and that the obtained data can be easily interpreted as a result.

Design, optimization, and validation procedures are critical to achieve both fitness of purpose and reliable serology test and, consequently, reliable results. One of the greatest challenges to improve rabies control and prevention strategies is to standardize and harmonize rabies serology results worldwide, requiring a continued collaboration between national and international laboratories, companies, and regulatory agencies.

**Author contribution** MCR, DF, and EG conducted the bibliography revision and wrote the manuscript. MCR performed the artwork. CP revised the manuscript. All the authors approved the manuscript.

**Declarations**

**Ethical approval** This article does not contain any studies with human participants or animals performed by any of the author.

**Conflict of interest** The authors declare no competing interests.

**References**

Banyard AC, Horton DL, Freuling C, Müller T, Fooks AR (2013) Control and prevention of canine rabies: the need for building laboratory-based surveillance capacity. Antivir Res 98:357–364. https://doi.org/10.1016/j.antiviral.2013.04.004

Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, Angov E (2008) Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific
antibodies. Malar J 7:1–10. https://doi.org/10.1186/1475-2875-7-129

Cliquet F, Aubert M, Sagné L (1998) Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantification of rabies-neutralising antibody. J Immunol Methods 212:79–87

Cliquet F, Sagné L, Schereffler JL, Aubert MF (2000) ELISA test for rabies antibody titration in orally vaccinated foxes sampled in the fields. Vaccine 18:3272–3279. https://doi.org/10.1016/S0264-410X(00)00127-4

Cliquet F, Müller T, Mutinelli F, Gerontsi S, Brochier B, Selhorst T, Schereffler JL, Kraftn N, Burow J, Schameait A, Schlüter H, Aubert M (2003) Standardisation and establishment of a rabies ELISA test in European laboratories for assessing the efficacy of oral fox vaccination campaigns. Vaccine 21:2986–2993. https://doi.org/10.1016/S0264-410X(03)00102-6

Cliquet F, McElhinney LM, Servat A, Boucher JM, Lowings JP, Goddard TA, Mansfield KL, Fooks AR (2004) Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats. J Virol Methods 117:1–8. https://doi.org/10.1016/j.jviromet.2003.12.001

Crawford KHD, Eguia R, Dingens AS, Loe NS, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD (2020) Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12. https://doi.org/10.3390/v12050513

Dascalu MA, Wasniewski M, Picard-D Meyer E, Servat A, Daraban C, Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Fontana D, Rodriguez MC, Garay E, Russo S, Prieto C (2020) Fallahi F (2005) Characterization of epitopes on the rabies virus glycoprotein. J Immunol Methods 212:79–87

Feyssaguet M, Dacheux L, Audry L, Compoint A, Morize JL, Blanchard CNC, Ferrara, Temperton (2018) Pseudotype neutralization assays: from laboratory bench to data analysis. Methods Protoc 1:8. https://doi.org/10.1016/j.mprot.2017.06.003

Cliquet F, Sagné L, Schereffler JL, Aubert MF (2000) ELISA test for rabies antibody virus neutralisation test. Virology 194:302–313. https://doi.org/10.1006/viro.1999.1162

Ma X, Niezgoda M, Blanton JD, Recuenco S, Rupprecht CE (2012) Evaluation of a new serological technique for detecting rabies virus antibodies following vaccination. Vaccine 30:5358–5362. https://doi.org/10.1016/j.vaccine.2012.06.037

Messenger S, Rupprecht CE (2015) An indirect fluorescent antibody test for the serological detection of rabies virus immunoglobulin G and immunoglobulin M antibodies. Second Edit, Elsevier Inc

Moore SM, Gordon CR, Chapter 13 - Measures of rabies immunity, Editor(s): Anthony R. Fooks, Alan C. Jackson, Rabies (Fourth Edition), Academic Press, 2020, Pages 445–479, https://doi.org/10.1016/B978-0-12-818705-0.00013-3

Moore SM, Gordon CR, Hanlon CA (2013) Chapter 12 - Measures of rabies immunity, Editor(s): Alan C. Jackson, Rabies (Third Edition), Academic Press, Pages 461–495, https://doi.org/10.1016/B978-0-12-396547-9.00021-3

Olivieri AC (2015) Practical guidelines for reporting results in single- and multi-component analytical calibration: a tutorial. Anal Chim Acta 652:161–171. https://doi.org/10.1016/j.aca.2015.01.017

Nie J, Liao Q, Wu J, Zhao C, HAO H, Liu H, Zhang L, Nie L, Qin H, Wang M, Lu Q, Li X, Sun Q, Liu J, Fan C, Huang W, Xu M, Wang Y (2020) Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 15:3699–3715. https://doi.org/10.1038/s41596-020-0394-5

Oliver MC (2015) Practical guidelines for reporting results in single- and multi-component analytical calibration: a tutorial. Anal Chim Acta 868:10–22. https://doi.org/10.1016/j.aca.2015.01.017

Schnell MJ, McGettigan JP, Wirblich C, Papaneri A (2010) The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol 8:51–61. https://doi.org/10.1038/nrmicro2260

Servat A, Cliquet F (2006) Collaborative study to evaluate a new ELISA test for monitoring the effectiveness of rabies vaccination in domestic carnivores. Vaccines 12. https://doi.org/10.3390/vaccines12030031
Shiota S, Mannen K, Matsumoto T, Yamada K, Yasui T, Takayama K, Kobayashi Y, Khawplod P, Gotoh K, Ahmed K, Iha H, Nishizono A (2009) Development and evaluation of a rapid neutralizing antibody test for rabies. J Virol Methods 161:58–62. https://doi.org/10.1016/j.jviromet.2009.05.018

Smith JS, Yager PA, Baer GM (1973) A rapid reproducible test for determining rabies neutralizing antibody. Bull World Health Organ 48:535–541

Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, Weiss RA (2005) Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis 11:411–416. https://doi.org/10.3201/eid1103.040906

Thi Nguyen KA, Nguyen TT, Nguyen DV, Ngo GC, Nguyen CN, Yamada K, Noguchi K, Ahmed K, Hoang HD, Nishizono A (2015) Evaluation of rapid neutralizing antibody detection test against rabies virus in human sera. Trop Med Health 43:111–116. https://doi.org/10.2149/tmh.2014-35

Wasniewski M, Cliquet F (2011) Evaluation of ELISA for detection of rabies antibodies in domestic carnivores. J Virol Methods 179:166–175. https://doi.org/10.1016/j.jviromet.2011.10.019

Wasniewski M, Guitot AL, Schereff JL, Tribout L, Mäh K, Cliquet F (2013) Evaluation of an ELISA to detect rabies antibodies in orally vaccinated foxes and raccoon dogs sampled in the field. J Virol Methods 187:264–270. https://doi.org/10.1016/j.jviromet.2012.11.022

Wasniewski M, Labbe A, Tribout L, Rieder J, Labadie A, Schereff JL, Cliquet F (2014) Evaluation of a rabies ELISA as an alternative method to seroneutralisation tests in the context of international trade of domestic carnivores. J Virol Methods 195:211–220. https://doi.org/10.1016/j.jviromet.2013.10.021

Wasniewski M, Almeida I, Baur A, Bedekovic T, Boncza D, Chaves LB, David D, De Benedictis P, Dobrostana M, Giraud P, Hostnik P, Jaceviciene I, Kenkles S, König M, Mäh K, Mojis M, Moore S, Mrenoski S, Müller T et al (2016) First international collaborative study to evaluate rabies antibody detection method for use in monitoring the effectiveness of oral vaccination programmes in fox and raccoon dog in Europe. J Virol Methods 238:77–85. https://doi.org/10.1016/j.jviromet.2016.10.006

Webster LT, Dawson JR (1935) Early diagnosis of rabies by mouse inoculation. Measurement of humoral immunity to rabies by mouse protection test. Proc Soc Exp Biol Med, 32:570

Welch RJ, Anderson BL, Litwin CM (2009) An evaluation of two commercially available ELISAs and one in-house reference laboratory ELISA for the determination of human anti-rabies virus antibodies. J Med Microbiol 58:806–810. https://doi.org/10.1099/jmm.0.006064-0

World Health Organization. (2018). WHO expert consultation on rabies: third report. World Health Organization. https://apps.who.int/iris/handle/10665/272364

Wright E, Temperton NJ, Marston DA, LM ME, Fooks AR, Weiss RA (2008) Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. J Gen Virol 89:2204–2213. https://doi.org/10.1099/vir.0.2008/000349-0

Yang R, Huang B, A R, Li W, Wang W, Deng Y, Tan W (2020) Development and effectiveness of Pseudotyped SARS-CoV-2 system as determined by neutralizing efficiency and entry inhibition test in vitro. Biosaf Heal:4–8. https://doi.org/10.1016/j.bsheal.2020.08.004

Zajac MD (2019) Development and evaluation of a rabies enzyme-linked immunosorbent assay (ELISA) targeting IgM and IgG in human sera by. https://doi.org/10.13140/RG.2.2.32365.54242

Zhang S, Liu Y, Zhang F, Hu R (2009) Competitive ELISA using a rabies glycoprotein-transformed cell line to semi-quantify rabies neutralizing-related antibodies in dogs. Vaccine 27:2108–2113. https://doi.org/10.1016/j.vaccine.2009.01.126

Zhang R, Yu P, Shan Y, Thirumeni N, Li M, Lv Y, Li J, Ren W, Huang L, Wei J, Sun Y, Zhu W, Sun L (2019) Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects. Vaccine 37:6060–6067. https://doi.org/10.1016/j.vaccine.2019.08.043

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.